Press Releases is unique and effective promotional tool offered from Worldpharmatoday.com aimed at bringing our client’s business message into limelight and more importantly make it reach their target audience. This feature can be utilized to launch new product, promoting existing Pharma product, publish business agreements, annual reports, financial results, corporate performances, important announcements or any important information that has to be conveyed to the target audience.
To add free press releases please click here.
Bristol-Myers Squibb to Present Data from 14 Abstracts on Orencia (abatacept) at the European League
Adding Investigational Agent Elotuzumab to Standard Treatment for Multiple Myeloma Significantly Reduced the Risk of Disease Progression, According to New Phase III Data from ELOQUENT-2 Trial Published in New England Journal of Medicine
U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo+Yervoy Regimen in Patients with Previously Untreated Advanced Melanoma
Opdivo (nivolumab) Demonstrates Superior Survival Compared to Standard of Care (docetaxel) for Previously-Treated Squamous Non-Small Cell Lung Cancer in Phase III Trial
Phase III CheckMate -067 Trial Demonstrates Superior Progression-Free Survival of Opdivo+Yervoy Regimen
Opdivo (nivolumab) First PD-1 Inhibitor to Demonstrate Superior Overall Survival Versus Standard of Care (docetaxel) in Previously-Treated Non-Squamous Non-Small Cell Lung Cancer in Pivotal Phase III Trial
Phase I/II Opdivo (nivolumab) Trial Shows Bristol-Myers Squibb’s PD-1 Immune Checkpoint Inhibitor is First to Demonstrate Anti-Tumor Activity In Patients With Hepatocellular Carcinoma
Page 1 of 74